Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-negative bacteria. We report our experience with cefiderocol-based combination therapies as “rescue” treatments in immunocompromised or critically ill patients or in patients with post-surgical infections who had...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavaro, Davide Fiore, Belati, Alessandra, Diella, Lucia, Stufano, Monica, Romanelli, Federica, Scalone, Luca, Stolfa, Stefania, Ronga, Luigi, Maurmo, Leonarda, Dell’Aera, Maria, Mosca, Adriana, Dalfino, Lidia, Grasso, Salvatore, Saracino, Annalisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227820/
https://www.ncbi.nlm.nih.gov/pubmed/34072342
http://dx.doi.org/10.3390/antibiotics10060652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227820/
https://www.ncbi.nlm.nih.gov/pubmed/34072342
http://dx.doi.org/10.3390/antibiotics10060652

Ejemplares similares